In 2020, the U.S. Food and Drug Administration (FDA) approved Opdivo and Yervoy for mesothelioma. The two immunotherapy drugs were approved as a first-line treatment option for...
Read PostMesothelioma is a rare cancer diagnosed in approximately 2,500 people in the U.S. each year. The average survival is 12-18 months, and surgery can help people extend their...
Read PostMesothelioma doctors believe that the best approach to treating the aggressive cancer known as mesothelioma is with multiple approaches. This strategy – called multimodal...
Read PostExpression Levels of Protein Linked to Longer Survival After Mesothelioma Surgery
By: Devin Golden
June 20, 2024
Scientists found a link between expression levels of a specific protein and survival of people with mesothelioma. According to research published in the medical journal Cancers,...
Read PostUPDATE (07/01/2024); This article was updated with information on how much each state receives in the Johnson & Johnson talc cancer settlement. The amounts for each state are...
Read PostThere are three cell types of the rare cancer called mesothelioma, and sarcomatoid mesothelioma is the most aggressive of the three. The average survival for people diagnosed with...
Read Post$260 Million Mesothelioma Verdict Awarded in Johnson & Johnson Lawsuit
By: Devin Golden
June 12, 2024
Johnson & Johnson is again on the wrong end of an extraordinary mesothelioma lawsuit. The health and beauty conglomerate was hit with a $260 million verdict in a mesothelioma...
Read PostConnecticut Jury Awards $15 Million Mesothelioma Verdict in Asbestos Lawsuit
By: Devin Golden
June 5, 2024
The family of a man who died in 2023 of mesothelioma was awarded a $15 million mesothelioma verdict in an asbestos lawsuit in Connecticut. According to the Middletown Press, a...
Read PostFDA Moving Keytruda Along in Approval Process for Mesothelioma
By: Devin Golden
Years after the U.S. Food and Drug Administration (FDA) approved the immunotherapy combination Opdivo and Yervoy for mesothelioma, the FDA is strongly considering a major approval...
Read Post